Approved-supplier lists with living scorecards. SCAR handling in weeks not months. Continuous monitoring for FDA warning letters, recalls, and certification lapses. Full supplier file producible in under 30 minutes.
FDA's post-QMSR inspection model under Compliance Program 7382.850 explicitly lists supplier audit reports as inspectable evidence. Undocumented phone-call audits and emailed summaries are now Form 483 exposure. Supplier quality is also the most common M&A red flag in a Class II diligence — because it's the easiest place to spot operational immaturity. Alterra AI closes both gaps with a single deployment.
Growing Class II SMBs typically end up with three symptoms — none of them fatal on their own, all of them costly under diligence or inspection:
Auto-updated scorecards per supplier covering defect rate, on-time delivery, SCAR aging, certification status, and inspection-history signals. Reviewer confirms status changes.
AI-drafted SCAR requests with reference NCRs and evidence. Automated follow-up cadence, escalation on aging, and closure-readiness checks with reviewer sign-off.
Watches FDA Warning Letters, recall notices, and ISO/CE certification lapses affecting your ASL. Alerts your team the day something changes — not at re-qualification time.
One-click generation of a complete supplier file: qualification, audits, agreements, scorecard history, SCARs, and re-qualification evidence. Inspector-ready in under 30 minutes.
| Metric | Before (typical) | After (target) | Source of estimate |
|---|---|---|---|
| Time to produce a supplier file | 4–8 hours (rushed) | < 30 minutes | Alterra AI project estimate |
| Median SCAR aging | 90–180 days | < 60 days | Alterra AI project estimate |
| ASL entries with stale certification | 15–35% | < 5% | Alterra AI project estimate |
| Supplier-related 483 risk | Present in ~40% of SMB inspections | -50% (estimated) | FDA 483 trend data (2024–2026) + Alterra modeling |
| External supplier-monitoring cost | Manual, ~$25K/yr equivalent | Included | Alterra AI project estimate |
Ranges reflect FDA post-2026 inspection posture (Ropes & Gray, MedDeviceGuide 2026), FDA 483 topic distribution, and Alterra project modeling. Individual results vary with ASL size and supplier risk mix.
What a diligence team will pull: supplier scorecard trends, SCAR aging, and evidence of a re-qualification cycle. When these show up as a clean, exportable dataset — not a Word document written last Tuesday — the whole quality-of-operations story upgrades. This is often the single largest non-financial value driver in a Class II acquisition.
Alterra AI's supplier workflow aligns to ISO 13485:2016 clause 7.4 (purchasing / control of externally provided products), 21 CFR 820.50 (now under QMSR), and FDA Compliance Program 7382.850's inspection elements for supplier audit reports and purchasing controls. Every audit record and SCAR action is a controlled process step with a signed reviewer.
Class II SMB with 10–100 approved suppliers, at least one supplier-related audit finding in the last 2 years, contract manufacturers or overseas suppliers in the mix, or diligence / M&A process expected inside 18 months.
Companies without an ASL at all (start with the QMS/QMSR business case), or businesses relying on a single distributor with no direct supplier exposure — a lighter engagement usually suffices.
48-hour read-only review of your top-3 supplier files, ASL, and open SCARs. Gap punch list ranked by inspection risk. Fixed-fee proposal within 5 business days.
Book the 48-hour Assessment